JP2005187339A - Light-resistant film-coated terbinafine hydrochloride tablet - Google Patents

Light-resistant film-coated terbinafine hydrochloride tablet Download PDF

Info

Publication number
JP2005187339A
JP2005187339A JP2003427120A JP2003427120A JP2005187339A JP 2005187339 A JP2005187339 A JP 2005187339A JP 2003427120 A JP2003427120 A JP 2003427120A JP 2003427120 A JP2003427120 A JP 2003427120A JP 2005187339 A JP2005187339 A JP 2005187339A
Authority
JP
Japan
Prior art keywords
film
tablet
coated
light
terbinafine hydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003427120A
Other languages
Japanese (ja)
Inventor
Keisuke Yamaguchi
恵介 山口
Masao Kawamoto
雅夫 河本
Akiko Miwa
明子 三輪
Nobumasa Zaisho
宣誠 税所
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iwaki Seiyaku Co Ltd
Original Assignee
Iwaki Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iwaki Seiyaku Co Ltd filed Critical Iwaki Seiyaku Co Ltd
Priority to JP2003427120A priority Critical patent/JP2005187339A/en
Publication of JP2005187339A publication Critical patent/JP2005187339A/en
Pending legal-status Critical Current

Links

Images

Abstract

<P>PROBLEM TO BE SOLVED: To provide a film-coated terbinafine hydrochloride tablet without discoloring by exposure to light. <P>SOLUTION: The film-coated terbinafine hydrochloride tablet is obtained by coating a terbinafine hydrochloride tablet with a polymer film colored with a titanium oxide pigment. <P>COPYRIGHT: (C)2005,JPO&NCIPI

Description

本発明は、塩酸テルビナフィンフィルムコート錠、詳しくは光を遮断するフィルムを施すことにより主薬の変質を防止し、変色しない安定な耐光性塩酸テルビナフィンフィルムコート錠に関する。   TECHNICAL FIELD The present invention relates to a terbinafine hydrochloride film-coated tablet, and more particularly to a stable light-resistant terbinafine hydrochloride film-coated tablet that prevents deterioration of the active ingredient by applying a film that blocks light and does not discolor.

塩酸テルビナフィンは抗真菌剤として使用されており、ラミシール(登録商標)錠という名称で既に市販されている(ノバルティス・ファルマ社製品)。裸錠(素錠)であるラミシール錠は光に対して主成分が不安定ある。
塩酸テルビナフィンは光により変質し易いため、ラミシール錠のプラスチック包装(PTP)を着色し、遮光を施している。しかし、PTPより取り出した後の安定性に問題がある。また、PTPに着色を施した製品は、内部の錠剤の異常を確認し難い。使用後のPTPの再利用にも着色のため支障を生じる。
Terbinafine hydrochloride is used as an antifungal agent and is already marketed under the name of Lamiseal (registered trademark) (product of Novartis Pharma). Lamiseal tablets, which are bare (uncoated) tablets, are unstable to light.
Since terbinafine hydrochloride is easily altered by light, the plastic packaging (PTP) of Lamiseal tablets is colored and shaded. However, there is a problem in stability after taking out from PTP. Moreover, it is difficult to confirm abnormality of an internal tablet in the product which colored PTP. Reuse of PTP after use also causes trouble due to coloring.

そこで本発明の課題は、光への暴露によって変色することがない、ポリマーフィルムでコートされた塩酸テルビナフィン錠を提供することである。   Therefore, an object of the present invention is to provide a terbinafine hydrochloride tablet coated with a polymer film, which does not change color by exposure to light.

前記課題は、主薬の変質を防止するため、酸化チタン顔料で着色したポリマーフィルムで塩酸テルビナフィン錠をコートすることによって解決される。また、苦味抑制の方法は、既に裸錠中に多量の甘味剤を含有させることが既知であるが、フィルム層に少量の甘味剤を含有させることで薄いフィルムで更に飲みやすい錠剤が得られた。更に1錠中のフィルム重量を0.5〜2.5重量%、好ましくは1〜2重量%にコントロールすることによりフィルムコート錠と裸錠とで溶出特性を変化させることなく、光に対する安定化及び苦味抑制を達成できる。   The above problem is solved by coating a terbinafine hydrochloride tablet with a polymer film colored with a titanium oxide pigment in order to prevent the main agent from being altered. In addition, the bitterness control method is already known to contain a large amount of sweetener in the bare tablet, but by adding a small amount of sweetener to the film layer, a tablet easier to drink with a thin film was obtained. . Furthermore, by controlling the film weight in one tablet to 0.5 to 2.5% by weight, preferably 1 to 2% by weight, the film-coated tablet and the bare tablet can be stabilized against light without changing the dissolution characteristics. And bitterness suppression can be achieved.

本発明においては、一般に主薬の変質を防止するために施されるコーティングに用いられるポリマーが使用され、その例としては、ヒドロキシプロピルセルロース(HPC)、ヒドロキシプロピルメチルセルロース(HPMC)、ポリビニルピロリドン(PVP)、プルランなどがあげられる。   In the present invention, a polymer generally used for coating applied to prevent deterioration of the active ingredient is used. Examples thereof include hydroxypropylcellulose (HPC), hydroxypropylmethylcellulose (HPMC), and polyvinylpyrrolidone (PVP). And pullulan.

着色コーティングフィルムは、上記ポリマーに酸化チタン顔料を1〜50重量%、好ましくは10〜30重量%加えることにより調製される。さらに任意の添加成分としてポリエチレングリコールのような可塑剤、タルクまたは炭酸カルシウムを含有させてもよい。更に甘味剤、例えば蔗糖、白糖、ソルビトール、サッカリン、アスパルテームを含有させることで苦味抑制効果が得られる。蔗糖、白糖、ソルビトールの含有量はフィルム成分中8〜48重量%、好ましくは16〜32重量%である。サッカリン、アスパルテームの含有量はフィルム成分中2〜48重量%、好ましくは8〜32重量%である。   The colored coating film is prepared by adding 1 to 50% by weight, preferably 10 to 30% by weight, of a titanium oxide pigment to the polymer. Further, a plasticizer such as polyethylene glycol, talc or calcium carbonate may be added as an optional additive component. Furthermore, a bitter taste suppressing effect can be obtained by adding a sweetener such as sucrose, sucrose, sorbitol, saccharin, and aspartame. The content of sucrose, sucrose, and sorbitol is 8 to 48% by weight, preferably 16 to 32% by weight in the film components. The content of saccharin and aspartame is 2 to 48% by weight, preferably 8 to 32% by weight, in the film components.

コーティング作業は、これらの成分を水、エタノール又は水・エタノール混液に溶解又は分散したコーティング液を裸錠に噴霧し、温風乾燥することによって行われる。   The coating operation is carried out by spraying a coating solution in which these components are dissolved or dispersed in water, ethanol, or a water / ethanol mixed solution onto a bare tablet and drying it with hot air.

以下、実施例1、2及び比較例1、2により本発明を説明する。   Hereinafter, the present invention will be described with reference to Examples 1 and 2 and Comparative Examples 1 and 2.

[実施例1]
1錠あたり、塩酸テルビナフィン140.625mg、結晶セルロース(旭化成工業 アビセルPH−101)44.375mg、カルボキシメチルスターチナトリウム10.0mgを混合し、結合剤であるヒドロキシプロピルセルロース3.0mgを精製水75.0mgに溶解したバインダー液を加えて湿式造粒し、温風乾燥した顆粒を打錠して裸錠とする。
この裸錠に、1錠あたりの被覆量がそれぞれ下記に示す量に成るようにコーティング液を噴霧乾燥によりコーティングした。
コーティング液
ヒドロキシプロピルメチルセルロース 2.16mg
プロピレングリコール 0.24mg
酸化チタン 0.60mg
44%エタノール(媒体) 27.0 mg
[Example 1]
Each tablet is mixed with 140.625 mg of terbinafine hydrochloride, 44.375 mg of crystalline cellulose (Asahi Kasei Avicel PH-101) and 10.0 mg of sodium carboxymethyl starch, and 3.0 mg of hydroxypropylcellulose as a binder is purified with 75. A binder solution dissolved in 0 mg is added and wet granulated, and the granules dried by warm air are compressed into plain tablets.
The uncoated tablet was coated with a coating solution by spray drying so that the coating amount per tablet was as shown below.
Coating solution Hydroxypropyl methylcellulose 2.16mg
Propylene glycol 0.24mg
Titanium oxide 0.60mg
44% ethanol (medium) 27.0 mg

[実施例2]
実施例1の裸錠に、1錠あたりの被覆量がそれぞれ下記に示す量に成るようにコーティング液を噴霧乾燥によりコーティングした。
コーティング液
ヒドロキシプロピルメチルセルロース 1.98mg
プロピレングリコール 0.24mg
酸化チタン 0.3 mg
精製白糖 0.48mg
44%エタノール(媒体) 27.0 mg
[Example 2]
The coating solution was coated on the plain tablet of Example 1 by spray drying so that the coating amount per tablet was as shown below.
Coating liquid Hydroxypropylmethylcellulose 1.98mg
Propylene glycol 0.24mg
Titanium oxide 0.3 mg
Purified white sugar 0.48mg
44% ethanol (medium) 27.0 mg

[比較例1]
実施例1の裸錠
[Comparative Example 1]
Uncoated tablet of Example 1

[比較例2]
ラミシール錠 製造番号 10260
使用期限 2004.8
[Comparative Example 2]
Lamiseal tablet serial number 10260
Expiration date 2004.8

1.安定性試験
保存条件
暴露光量:120万Lux・Hr
温度 :25℃
包装形態: 遮光 アルミ包装
曝光 シャーレ開放
結果を表1に示す。
1. Stability test storage conditions Exposure light level: 1,200,000 Lux · Hr
Temperature: 25 ° C
Packaging style: Shading Aluminum packaging
Exposure Petri dish release The results are shown in Table 1.

Figure 2005187339
本発明のフィルムコーテイング錠は、外観変化を認めず安定であった。
Figure 2005187339
The film coating tablet of the present invention was stable with no change in appearance.

2.苦味アンケート
実施方法
7名についてアンケートを行い、錠剤を静止した舌の上に60秒間のせ、苦味を感じた人数を調査した。
苦味アンケート結果を表2に示す。
2. Bitter taste questionnaire implementation method A questionnaire was conducted on seven people, and the tablets were placed on a stationary tongue for 60 seconds to investigate the number of people who felt bitterness.
The bitterness questionnaire results are shown in Table 2.

Figure 2005187339
本発明のフィルムコーテイング錠は、60秒で苦味を認めなかった。
Figure 2005187339
The film coating tablet of the present invention showed no bitterness in 60 seconds.

3.溶出試験
試験方法
日本薬局方の一般試験法、溶出試験、パドル法に従って行った。
pH:4.0
回転数:50rpm
緩衝液:酢酸・酢酸ナトリウム緩衝液(0.05mol/L)
定量方法:紫外可視吸光度測定法
結果を表3および図1に示す。表3および図1から明らかなように、本発明のフィルムコート錠と裸錠とでは溶出性は同等であり、溶出特性に変化は認められなかった。
3. Dissolution Test Test Method The dissolution test was performed according to the Japanese Pharmacopoeia general test method, dissolution test, and paddle method.
pH: 4.0
Rotation speed: 50rpm
Buffer: Acetic acid / sodium acetate buffer (0.05 mol / L)
Quantitative method: UV-visible absorbance measurement method The results are shown in Table 3 and FIG. As is apparent from Table 3 and FIG. 1, the film-coated tablet and the bare tablet of the present invention had the same dissolution property, and no change was observed in the dissolution property.

Figure 2005187339
Figure 2005187339

実施例および比較例の各錠剤の溶出曲線を示す。The elution curve of each tablet of an Example and a comparative example is shown.

Claims (3)

酸化チタン顔料で着色したポリマーフィルムでコートされた耐光性塩酸テルビナフィンフィルムコート錠。   Light-resistant terbinafine hydrochloride film-coated tablet coated with a polymer film colored with a titanium oxide pigment. 前記着色フィルム層に甘味剤を更に含む請求項1に記載の耐光性塩酸テルビナフィンフィルムコート錠。   The light-resistant terbinafine hydrochloride film-coated tablet according to claim 1, further comprising a sweetener in the colored film layer. 1錠中の前記着色フィルムが0.5〜2.5重量%である請求項2に記載の耐光性塩酸テルビナフィンフィルムコート錠。
The light-resistant terbinafine hydrochloride film-coated tablet according to claim 2, wherein the colored film in one tablet is 0.5 to 2.5% by weight.
JP2003427120A 2003-12-24 2003-12-24 Light-resistant film-coated terbinafine hydrochloride tablet Pending JP2005187339A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003427120A JP2005187339A (en) 2003-12-24 2003-12-24 Light-resistant film-coated terbinafine hydrochloride tablet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003427120A JP2005187339A (en) 2003-12-24 2003-12-24 Light-resistant film-coated terbinafine hydrochloride tablet

Publications (1)

Publication Number Publication Date
JP2005187339A true JP2005187339A (en) 2005-07-14

Family

ID=34786478

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003427120A Pending JP2005187339A (en) 2003-12-24 2003-12-24 Light-resistant film-coated terbinafine hydrochloride tablet

Country Status (1)

Country Link
JP (1) JP2005187339A (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015509941A (en) * 2012-02-16 2015-04-02 テバ ファーマシューティカル インダストリーズ リミティド N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, its formulation and use
JP2017031103A (en) * 2015-08-03 2017-02-09 大原薬品工業株式会社 Pramipexole formulation packaging with improved light stability
JP2019094295A (en) * 2017-11-22 2019-06-20 沢井製薬株式会社 Dasatinib Anhydride-Containing Preparation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0624987A (en) * 1992-07-09 1994-02-01 Tanabe Seiyaku Co Ltd Nicergolin-containing tablet
JPH09183728A (en) * 1987-06-24 1997-07-15 Bayer Ag Preparation of solid medicine
WO1997039752A1 (en) * 1996-04-24 1997-10-30 Shionogi & Co., Ltd. Sertindole preparation and process for the production thereof
JP2000044464A (en) * 1998-08-03 2000-02-15 Taisho Pharmaceut Co Ltd Film-coated tablet
WO2002060446A1 (en) * 2001-01-29 2002-08-08 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
WO2003022267A1 (en) * 2001-07-20 2003-03-20 Novartis Ag Pharmaceutical compositions containing terbinafin and use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09183728A (en) * 1987-06-24 1997-07-15 Bayer Ag Preparation of solid medicine
JPH0624987A (en) * 1992-07-09 1994-02-01 Tanabe Seiyaku Co Ltd Nicergolin-containing tablet
WO1997039752A1 (en) * 1996-04-24 1997-10-30 Shionogi & Co., Ltd. Sertindole preparation and process for the production thereof
JP2000044464A (en) * 1998-08-03 2000-02-15 Taisho Pharmaceut Co Ltd Film-coated tablet
WO2002060446A1 (en) * 2001-01-29 2002-08-08 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
WO2003022267A1 (en) * 2001-07-20 2003-03-20 Novartis Ag Pharmaceutical compositions containing terbinafin and use thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015509941A (en) * 2012-02-16 2015-04-02 テバ ファーマシューティカル インダストリーズ リミティド N-ethyl-N-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, its formulation and use
JP2017031103A (en) * 2015-08-03 2017-02-09 大原薬品工業株式会社 Pramipexole formulation packaging with improved light stability
JP2019094295A (en) * 2017-11-22 2019-06-20 沢井製薬株式会社 Dasatinib Anhydride-Containing Preparation
US11406600B2 (en) 2017-11-22 2022-08-09 Sawai Pharmaceutical Co., Ltd. Anhydrous dasatinib-containing preparation
JP7166754B2 (en) 2017-11-22 2022-11-08 沢井製薬株式会社 Formulations containing dasatinib anhydrate

Similar Documents

Publication Publication Date Title
KR910002641B1 (en) Peroral preparation of an acid unstable compound
ES2255521T3 (en) COATING.
US9789112B2 (en) Oral pharmaceutical film formulation for bitter tasting drugs
JP5365777B2 (en) Ramosetron solid pharmaceutical composition stable to light
TW200815032A (en) Use of polyols to obtain stable polymorphous forms of rifaximin
JPWO2013054872A1 (en) Tablet containing 7- [4- (4-benzo [b] thiophen-4-yl-piperazin-1-yl) butoxy] -1H-quinolin-2-one or a salt thereof
WO2006011638A1 (en) Film coated tablet having plural coats
ES2245071T3 (en) PROCEDURE TO OBTAIN A PREPARATION OF DELAYED TRAMADOL WITH A STABLE RELEASE PROFILE IN STORAGE WITHOUT NEED TO TREAT THE COATED PRODUCT THERMALLY.
JP3689104B2 (en) Stable oral solid pharmaceutical composition
JP2019156857A (en) Montelukast sodium formulation
CA3161914A1 (en) Transmucosal therapeutic system containing agomelatine
CZ301812B6 (en) Orally applicable composition containing quinolone antibiotics and process for preparing thereof
KR20070044323A (en) Stabilized pharmaceutical oral preparation containing clopidogrel bisulfate
JP2013035797A (en) Tablet containing pitavastatin
JP2005187339A (en) Light-resistant film-coated terbinafine hydrochloride tablet
JP4972563B2 (en) New film-coated tablets
JP2002316928A (en) Coated tablet and method for preventing peeling of coated tablet
RU2117476C1 (en) Ranitidine tablet covered by hydroxypropylmethylcellulose and a method of cover applying
JP2009023943A (en) Method for film coating
JPH115736A (en) Ibuprofen-containing tablet
AU2020302262A1 (en) Transmucosal therapeutic system containing agomelatine
JP2006143598A (en) Medicine composition controlling change in color with time
JP4824224B2 (en) Sugar-coating preparations
WO2003077829A2 (en) Process for preparation of a pharmaceutical composition containing acid labile compounds
JP6339800B2 (en) Miglitol-containing coating formulation

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100302

A02 Decision of refusal

Effective date: 20100629

Free format text: JAPANESE INTERMEDIATE CODE: A02